Literature DB >> 11577031

Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability.

Z Mallat1, A Corbaz, A Scoazec, P Graber, S Alouani, B Esposito, Y Humbert, Y Chvatchko, A Tedgui.   

Abstract

Interleukin (IL)-18 is the interferon-gamma-inducing factor and has other proinflammatory properties. The precise role of IL-18 in immunoinflammatory diseases remains poorly understood. In this study, we show that in vivo electrotransfer of an expression-plasmid DNA encoding for murine IL-18 binding protein (BP) (the endogenous inhibitor of IL-18) prevents fatty streak development in the thoracic aorta of apoE knockout mice and slows progression of advanced atherosclerotic plaques in the aortic sinus. More importantly, transfection with the IL-18BP plasmid induces profound changes in plaque composition (decrease in macrophage, T cell, cell death, and lipid content and increase in smooth muscle cell and collagen content) leading to a stable plaque phenotype. These results identify for the first time a critical role for IL-18/IL-18BP regulation in atherosclerosis and suggest a potential role for IL-18 inhibitors in reduction of plaque development/progression and promotion of plaque stability. The full text of this article is available at http://www.circresaha.org.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11577031     DOI: 10.1161/hh1901.098735

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  109 in total

1.  Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice.

Authors:  Koichi Kozaki; Wolfgang E Kaminski; Jingjing Tang; Stan Hollenbach; Per Lindahl; Carol Sullivan; Jin-Chen Yu; Keith Abe; Paul J Martin; Russell Ross; Christer Betsholtz; Neill A Giese; Elaine W Raines
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

2.  Inflammasomes in cardiovascular diseases.

Authors:  Nisha Jain Garg
Journal:  Am J Cardiovasc Dis       Date:  2011-09-10

3.  Panhistone deacetylase inhibitors inhibit proinflammatory signaling pathways to ameliorate interleukin-18-induced cardiac hypertrophy.

Authors:  Gipsy Majumdar; Robert J Rooney; I Maria Johnson; Rajendra Raghow
Journal:  Physiol Genomics       Date:  2011-09-27       Impact factor: 3.107

4.  Elevated serum levels of interleukin-18 are associated with insulin resistance in women with polycystic ovary syndrome.

Authors:  Yi-fei Zhang; Yi-sheng Yang; Jie Hong; Wei-qiong Gu; Chun-fang Shen; Min Xu; Peng-fei Du; Xiao-ying Li; Guang Ning
Journal:  Endocrine       Date:  2006-06       Impact factor: 3.633

5.  Quiescin sulfhydryl oxidase (QSOX) is expressed in the human atheroma core: possible role in apoptosis.

Authors:  Claudia R de Andrade; Beatriz S Stolf; Victor Debbas; Daniela S Rosa; Jorge Kalil; Veronica Coelho; Francisco R M Laurindo
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-11-09       Impact factor: 2.416

Review 6.  The role of adaptive T cell immunity in atherosclerosis.

Authors:  Ziad Mallat; Soraya Taleb; Hafid Ait-Oufella; Alain Tedgui
Journal:  J Lipid Res       Date:  2008-12-02       Impact factor: 5.922

7.  T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm.

Authors:  Uwe Schönbeck; Galina K Sukhova; Norbert Gerdes; Peter Libby
Journal:  Am J Pathol       Date:  2002-08       Impact factor: 4.307

Review 8.  The IL-1 family: regulators of immunity.

Authors:  John E Sims; Dirk E Smith
Journal:  Nat Rev Immunol       Date:  2010-01-18       Impact factor: 53.106

Review 9.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

Review 10.  Innate and adaptive immunity in atherosclerosis.

Authors:  René R S Packard; Andrew H Lichtman; Peter Libby
Journal:  Semin Immunopathol       Date:  2009-05-16       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.